The United States Food and Drug Administration (FDA) initially approved tedizolid in 2014 for the treatment of acute bacterial skin and skin structure infections in adults, and in 2020, the FDA increased the clearance of tedizolid to include the treatment of pediatric patients aged 12 and older with the same condition. Clinical surveillance isolates from U.S. pediatric patients with skin and skin structure infections were used to compare tedizolid’s efficacy to that of a group of comparators. Between 2015 and 2019, a total of 2,747 gram-positive organisms were obtained from children (≤17 years old) with skin and skin structure illnesses. Using reference broth microdilution methods, researchers determined the sensitivity of the isolates to tedizolid and comparators acquired from 33 U.S. medical institutions. Main pathogen susceptibility results were divided into 4 age groups: less than equal to 1-year-old (851 isolates), 1-2 years (623 isolates), 3-5 years (754 isolates), and 17 years (851 isolates) (519). The most common pathogen found in patients of all ages was staphylococcus aureus (n=2163), followed by β-hemolytic streptococci (n=460). No matter the age range, S. aureus was inhibited by tedizolid. This includes 41.0% of MRSA isolates. The highest prevalence of methicillin-resistant S. aureus (MRSA) was observed in those aged 0-12 months (45.0%), while the lowest prevalence was observed in those aged 13-17 years (32.7%). About 100% of S. aureus isolates were susceptible to linezolid, daptomycin, and vancomycin; however, susceptibility rates for clindamycin (81.3–98.5%), tetracycline (91.6–97.1%), and trimethoprim-sulfamethoxazole (97.0%–100%) varied by age and methicillin resistance profile. Overall, all of the gram-positive pathogens in this sample were suppressed by the combination of tedizolid, linezolid, daptomycin, and vancomycin. Tedizolid showed impressive activity against a wide range of gram-positive organisms, including MRSA isolates, that cause infection of the skin and skin structures in children.